Open-Label Safety Study of AXS-05 in Subjects With Depression
Open-Label Safety Study of AXS-05 in Subjects With Depression
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder
 (MDD), including treatment resistant depression.
A multi-center, open-label, long-term study to evaluate the safety and efficacy of AXS-05 in
 patients with major depressive disorder, including treatment resistant depression, treated
 for up to one year.
Inclusion Criteria:

 -  Diagnosis of major depressive disorder, including treatment resistant depression

 -  Body mass index (BMI) between 18 and 40 kg/m^2, inclusive

 -  Agree to use adequate method of contraception for the duration of the study

 -  Additional criteria may apply

 Exclusion Criteria:

 -  Suicide risk

 -  Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study

 -  Additional criteria may apply